Swedish Authority Closes Probe into Orphan Drug Pricing

Stockholm, October 15, 2025 – The Swedish Competition Authority has closed its investigation into the pricing of the rare disease drug Namuscla, concluding that while treatment costs in Sweden have risen sharply, the evidence does […]

Competition Today

FREE
VIEW